Literature DB >> 20933013

Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells.

Jose De Salort1, Jordi Sintes, Laia Llinàs, Jessica Matesanz-Isabel, Pablo Engel.   

Abstract

The SLAM (CD150) family receptors are leukocyte cell-surface glycoproteins involved in leukocyte activation. These molecules and their adaptor protein SAP contribute to the effective germinal center formation, generation of high-affinity antibody-secreting plasma cells, and memory B cells, thereby facilitating long-term humoral immune response. Multi-color flow cytometric analysis was performed to determine the expression of CD48 (SLAMF2), CD84 (SLAMF5), CD150 (SLAM or SLAMF1), CD229 (Ly9 or SLAMF3), CD244 (2B4 or SLAMF4), CD319 (CRACC, CS1, or SLAMF7), and CD352 (NTB-A or SLAMF6) on human cell lines and B-cell subsets. The following subsets were assessed: pro-B, pre-B, immature-B, and mature-B cells from bone marrow; transitional and B1/B2 subsets from peripheral blood; and naïve, pre-germinal center, germinal center, memory, plasmablasts, and plasma cells from tonsil and spleen. All receptors were expressed on B cells, with the exception of CD244. SLAM family molecules were widely distributed during B-cell development, maturation and terminal differentiation into plasmablasts and plasma cells, but their expression among various B-cell subsets differed significantly. Such heterogeneous expression patterns suggest that SLAM molecules play an essential and non-redundant role in the control of humoral immune responses.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20933013     DOI: 10.1016/j.imlet.2010.09.021

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  29 in total

1.  Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis.

Authors:  Fang Zhao; Jennifer L Cannons; Mala Dutta; Gillian M Griffiths; Pamela L Schwartzberg
Journal:  Immunity       Date:  2012-06-07       Impact factor: 31.745

Review 2.  Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Tim Luetkens; Djordje Atanackovic
Journal:  Oncoimmunology       Date:  2017-03-28       Impact factor: 8.110

3.  CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Authors:  Sara Yousef; Magdalena Kovacsovics-Bankowski; Mohamed E Salama; Neelam Bhardwaj; Mary Steinbach; Amanda Langemo; Tibor Kovacsovics; James Marvin; Mascha Binder; Jens Panse; Nicolaus Kröger; Tim Luetkens; Djordje Atanackovic
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Influence of Plasma Cell Niche Factors on the Recruitment and Maintenance of IRF4hi Plasma Cells and Plasmablasts in Vaccinated, Simian Immunodeficiency Virus-Infected Rhesus Macaques with Low and High Viremia.

Authors:  Julia M Shaw; Leia K Miller-Novak; Venkatramanan Mohanram; Katherine McKinnon; Thorsten Demberg; Diego A Vargas-Inchaustegui; David Venzon; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

5.  Critical Role for SLAM/SAP Signaling in the Thymic Developmental Programming of IL-17- and IFN-γ-Producing γδ T Cells.

Authors:  Oliver Dienz; Victoria L DeVault; Shawn C Musial; Somen K Mistri; Linda Mei; Aleksandr Baraev; Julie A Dragon; Dimitry Krementsov; Andre Veillette; Jonathan E Boyson
Journal:  J Immunol       Date:  2020-02-05       Impact factor: 5.422

6.  Repository corticotrophin injection exerts direct acute effects on human B cell gene expression distinct from the actions of glucocorticoids.

Authors:  A L Benko; C A McAloose; P M Becker; D Wright; T Sunyer; Y I Kawasawa; N J Olsen; W J Kovacs
Journal:  Clin Exp Immunol       Date:  2018-01-12       Impact factor: 4.330

Review 7.  Hematopoietic stem and progenitor cells directly participate in host immune response.

Authors:  Olusola Jumoke Daramola; Stephen Osasan; Hebah Ali; Perpetua Emeagi
Journal:  Am J Stem Cells       Date:  2021-06-15

Review 8.  Receptor-mediated cell entry of paramyxoviruses: Mechanisms, and consequences for tropism and pathogenesis.

Authors:  Chanakha K Navaratnarajah; Alex R Generous; Iris Yousaf; Roberto Cattaneo
Journal:  J Biol Chem       Date:  2020-01-16       Impact factor: 5.157

Review 9.  Elotuzumab as a novel anti-myeloma immunotherapy.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Mary Steinbach; Janet Weidner; Tim Luetkens; Djordje Atanackovic
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

10.  Development and characterization of domain-specific monoclonal antibodies produced against human SLAMF9.

Authors:  Olga Volkova; Sergey Guselnikov; Ludmila Mechetina; Nicolai Chikaev; Konstantin Baranov; Sergey Kulemzin; Evdokiya Reshetnikova; Alexander Najakshin; Alexander Taranin
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.